Abstract:1862 Objectives: To prepare 99mTc-IT-rituximab, a novel sentinel lymphoscintigraphy agent, and evaluate its ability in detecting the sentinel lymph node. Methods: Rituximab was radiolabeled with 99mTc via 2-iminothiolane (2-IT). The resulting 99mTc-IT-Rituximab were analysed for number of free sulfhydryl groups. The integrity of IT-rituximab was evaluated by SDS-PAGE, ELISA, which could evaluated the optimal modifying conditions. The immunological biology of 99mTc-IT-rituximab was evaluated by flow-cytometric analysis (FCA). Comparing the radiocolloid, 99mTc-IT-Rituximab was evaluated with biological distribution results, and image of sentinel lymph node (SLN) was obtained at 30min-24h postinjection with 99mTc-IT-rituximab in mice. The influenced factors on the imaging by the injecting dosage and volume were also observed in mice. Results: Optimal conditions for modifying Rituximab involved a 10:1 molar ratio of 2-IT : protein in 4°C, the number of apparent thiol produced were 2.1 per IT-Rituximab. 99mTc-IT-rituximabwas stable for 24 h at 37°C in human serum. 99mTc-IT-rituximab was proved to have the similar immunological character with rituximab by SDS-PAGE, ELISA and FCA. Its binding rate of B lymphoma cell line Raji cell is 69.4%. After subcutaneous injection into the foot pads of mice, 99mTc-IT-rituximab showed high accumulationn the knee. The mean %ID of the popliteal lymph node at 1, 4, 8, and 24 h was (2.33±0.13)%, (2.72±0.12)%, (3.71±0.28)%, and (4.49±0.43)%, respectively. The mean %ID of NSLN was less than 0.2% at each time point. With increasing the injected dose or volume the %ID of SLN would decrease, while the %ID of NSLN would increase gradually. 99mTc-IT-rituximab exhibited faster injection site clearance than did 99mTc-SC and 99mTc-DX, %ID of the rear paws was (22.14±2.08)% at 24 h after administration. In mice, the results of dynamic SLN mapping show that SLN could be seen within a wide range from 30 min to 24 h postinjection. The higher order nodes had not been seen all the time. 99mTc-IT-rituximab was mainly excreted by kidney, other tissues exhibited less than 1 percent of the injected dose at all time points. For radiocolloid, the higher echelon node extraction was significantly higher. The 99mTc-SC and 99mTc-DX %ID of the second-order node was (4.93±0.37) % and (8.54±0.78) % at 2 h. The uptake of second echelon for 99mTc-HSA was also higher than 99mTc-IT-rituximab. Conclusions: 99mTc-IT-Rituximab, as a tracer to mapping SLN, could predict the status of SLNs reliably.

The distribution of CIK cell after intravenous injection in animals

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

Study of Biodistribution Properties of a New Myocardial Imaging Agent 99Tcm-N-DBODC5

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

Visualization of Mouse Cardiac Microvascular Blood Flow and Distribution of Serum Protein with in Vivo Cryotechnique

Direct radio-labeling of 99Tcm-IgG and its biologic distribution study

Efficient Expansion of the Cytokine-Induced Natural Killer Cells from Human Peripheral Blood in Vitro

Biodistribution of iodine-131-labled chimeric monoclonal antibody in patients following intratumoral administraion in advanced lung carcinoma

Animal SPECT/CT imaging and radiation dosimetry of~(99m)Tc-HYNIC-TOC

Pharmacokinetic Study Of~(125) I-CTLA4Ig:Absorption,distribution,and Excretion after a Single Intravenous Administration to Rats

Radiolabeling and animal experimental studies of anti-breast cancer McAb 6C6 and mouse-human chimeric antibody 6C6CHI

Preparation and Preliminary Biological Evaluation of 11C-L-spd

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Study on the Distribution and Elimination of the New Hormone Irisin in Vivo: New Discoveries Regarding Irisin

18 F-FHBG PET-CT Reporter Gene Imaging of Adoptive CIK Cell Transfer Immunotherapy for Breast Cancer in a Mouse Model

Transplanted Murine Tumours SPECT Imaging with 99mTc Delivered with an Artificial Recombinant Protein

Study of Distribution and Antisense Imaging for 99Mtc-Ason-egf in Breast Cancer-Bearing Nude Mouse Models

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Development and animal study of sentinel lymph node imaging with a novel radiotracer

Evaluation of Cytokine-Induced Killer Cells in Activating Lymphocytes of Tumorbearing Patients in Vivo